European Regulator Expands Ozempic Probe To Include Other Weight Loss Drugs Over Suicide Risks
Portfolio Pulse from Benzinga Newsbot
The European Union’s drug regulator has expanded its investigation into the risk of suicidal thoughts and self-injury among patients taking weight loss and diabetes medications, including those produced by Novo Nordisk. The probe could potentially involve Eli Lilly‘s diabetes drug Mounjaro and similar products under development by Pfizer and Amgen. The investigation could potentially establish new side effects associated with blockbuster drugs such as Wegovy and Ozempic.
July 12, 2023 | 2:33 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amgen's products under development could potentially be included in the EU regulator's investigation into suicide risks.
If Amgen's under-development products are included in the investigation, it could delay their launch and negatively impact the company's future sales.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
Eli Lilly's diabetes drug Mounjaro could potentially be included in the EU regulator's investigation into suicide risks.
If Eli Lilly's Mounjaro is included in the investigation, it could negatively impact the company's reputation and sales.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Novo Nordisk's weight loss and diabetes drugs are under investigation by the EU regulator for potential suicide risks.
The investigation into potential suicide risks associated with Novo Nordisk's drugs could negatively impact the company's reputation and sales if new side effects are established.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's products under development could potentially be included in the EU regulator's investigation into suicide risks.
If Pfizer's under-development products are included in the investigation, it could delay their launch and negatively impact the company's future sales.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 60